Elevated Rictor expression is associated with tumor progression and poor prognosis in patients with gastric cancer

Biochemical and Biophysical Research Communications

Volumn 464, Issue 2, 2015, Pages 534-540

  Bian, Yuhai ^a   Wang, Zhengshi ^a   Xu, Jia ^a   Zhao, Wenyi ^a   Cao, Hui ^a   Zhang, Zhigang ^b  

^a SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b School of Medicine   (China)

Author keywords

Gastric cancer; pAktSer473; Prognosis; pS6; Rictor

Indexed keywords

MAMMALIAN TARGET OF RAPAMYCIN COMPLEX 2; PROTEIN KINASE B; PROTEIN S6; RAPAMYCIN INSENSITIVE COMPANION OF MAMMALIAN TARGET OF RAPAMYCIN; UNCLASSIFIED DRUG; CARRIER PROTEIN; RICTOR PROTEIN, HUMAN; SERINE; TUMOR MARKER;

ADULT; ARTICLE; CANCER PROGNOSIS; CANCER SIZE; CANCER SURVIVAL; DISEASE ASSOCIATION; DISEASE SEVERITY; DISTANT METASTASIS; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PRIORITY JOURNAL; RECURRENCE FREE SURVIVAL; STOMACH CANCER; TUMOR INVASION; TUMOR THROMBUS; CHEMISTRY; DISEASE COURSE; ENZYMOLOGY; METABOLISM; MIDDLE AGED; PATHOLOGY; PROGNOSIS; STOMACH TUMOR;

CARRIER PROTEINS; DISEASE PROGRESSION; FEMALE; HUMANS; MALE; MIDDLE AGED; PROGNOSIS; PROTO-ONCOGENE PROTEINS C-AKT; SERINE; STOMACH NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 84938293293     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2015.07.001     Document Type: Article

References (31)

1. L.A. Torre, F. Bray, R.L. Siegel, and et al. Global cancer statistics, 2012, CA Cancer. J. Clin. 65 2015 87 108
2. L. Yang Incidence and mortality of gastric cancer in China World. J. Gastroenterol. 12 2006 17 20
3. C. Betz, and M.N. Hall Where is mTOR and what is it doing there? J. Cell. Biol. 203 2013 563 574
4. D.A. Guertin, and D.M. Sabatini Defining the role of mTOR in cancer Cancer. Cell. 12 2007 9 22
5. H. Pópulo, J.M. Lopes, and P. Soares The mTOR signalling pathway in human cancer Int. J. Mol. Sci. 13 2012 1886 1918
6. G. Yu, J. Wang, Y. Chen, and et al. Overexpression of phosphorylated mammalian target of rapamycin predicts lymph node metastasis and prognosis of chinese patients with gastric cancer Clin. Cancer. Res. 15 2009 1821 1829
7. A. Ohtsu, J.A. Ajani, Y.X. Bai, and et al. Everolimus for previously treated advanced gastric cancer: results of the randomized, double-blind, phase III GRANITE-1 study J. Clin. Oncol. 31 2013 3935 3943
8. M. Laplante, and D.M. Sabatini mTOR signaling in growth control and disease Cell. 149 2012 274 293
9. D.D. Sarbassov, D.A. Guertin, S.M. Ali, and et al. Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex Science 307 2005 1098 1101
10. X. Wan, B. Harkavy, N. Shen, and et al. Rapamycin induces feedback activation of Akt signaling through an IGF-1R-dependent mechanism Oncogene 26 2007 1932 1940
11. J.S. Carew, K.R. Kelly, and S.T. Nawrocki Mechanisms of mTOR inhibitor resistance in cancer therapy Target. Oncol. 6 2011 17 27
12. H. Li, J. Lin, X. Wang, and et al. Targeting of mTORC2 prevents cell migration and promotes apoptosis in breast cancer Breast. Cancer. Res. Treat. 134 2012 1057 1066
13. F. Zhang, X.F. Zhang, M.H. Li, and et al. mTOR complex component Rictor interacts with PKCζ and regulates cancer cell metastasis Cancer. Res. 70 2010 9360 9370
14. D.A. Guertin, D.M. Stevens, M. Saitoh, and et al. mTOR complex 2 is required for the development of prostate cancer induced by Pten loss in mice Cancer. Cell. 15 2009 148 159
15. P. Gulhati, Q. Cai, J. Li, and et al. Targeted inhibition of mammalian target of rapamycin signaling inhibits tumorigenesis of colorectal cancer Clin. Cancer. Res. 15 2009 7207 7216
16. P. Gulhati, K.A. Bowen, J. Liu, and et al. mTORC1 and mTORC2 regulate EMT, motility, and metastasis of colorectal cancer via RhoA and Rac1 signaling pathways Cancer. Res. 71 2011 3246 3256
17. R.J. Motzer, B. Escudier, S. Oudard, and et al. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial Lancet 372 2008 449 456
18. M.E. Pavel, J.D. Hainsworth, E. Baudin, and et al. Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): a randomised, placebo-controlled, phase 3 study Lancet 378 2011 2005 2012
19. M. Kaibori, N. Shikata, T. Sakaguchi, and et al. Influence of rictor and raptor expression of mTOR signaling on long-term outcomes of patients with hepatocellular carcinoma Dig. Dis. Sci. 60 2015 919 928
20. S.Y. Wen, C.H. Li, Y.L. Zhang, and et al. Rictor is an independent prognostic factor for endometrial carcinoma Int. J. Clin. Exp. Pathol. 7 2014 2068 2078
21. W. Jia, A.J. Sanders, G. Jia, and et al. Expression of the mTOR pathway regulators in human pituitary adenomas indicates the clinical course Anticancer. Res. 33 2013 3123 3131
22. U. Wazir, R.F. Newbold, W.G. Jiang, and et al. Prognostic and therapeutic implications of mTORC1 and rictor expression in human breast cancer Oncol. Rep. 29 2013 1969 1974
23. D. Murakami, S. Tsujitani, T. Osaki, and et al. Expression of phosphorylated Akt (pAkt) in gastric carcinoma predicts prognosis and efficacy of chemotherapy Gastric. Cancer 10 2007 45 51
24. C. Cinti, C. Vindigni, A. Zamparelli, and et al. Activated Akt as an indicator of prognosis in gastric cancer Virchows. Arch. 453 2008 449 455
25. N.K. Agarwal, C.H. Chen, H. Cho, and et al. Rictor regulates cell migration by suppressing RhoGDI2 Oncogene 32 2013 2521 2526
26. I. Serrano, P.C. McDonald, F.E. Lock, and et al. Role of the integrin-linked kinase (ILK)/Rictor complex in TGFβ-1-induced epithelial-mesenchymal transition (EMT) Oncogene 32 2013 50 60
27. M. Andrikopoulou, N. Salakos, E. Deligeoroglou, and et al. The role of mTOR signaling pathway in premalignant and malignant cervical lesions Eur. J. Gynaecol. Oncol. 36 2015 36 43
28. L. Annovazzi, M. Mellai, V. Caldera, and et al. mTOR, S6 and AKT expression in relation to proliferation and apoptosis/autophagy in glioma Anticancer. Res. 29 2009 3087 3094
29. L. Zhou, Y. Huang, J. Li, and et al. The mTOR pathway is associated with the poor prognosis of human hepatocellular carcinoma Med. Oncol. 27 2010 255 261
30. J.M. McDonald, C.E. Pelloski, A. Ledoux, and et al. Elevated phospho-S6 expression is associated with metastasis in adenocarcinoma of the lung Clin. Cancer. Res. 14 2008 7832 7837
31. G. Betts, H. Valentine, S. Pritchard, and et al. FGFR2, HER2 and cMet in gastric adenocarcinoma: detection, prognostic significance and assessment of downstream pathway activation Virchows. Arch. 464 2014 145 156